Pilot studies can identify signals worth testing, but their most favorable findings should not be detached from sample size and the number of outcomes examined. Primary study
What was studied
Nineteen young people with cystic fibrosis were randomized to buffered inhaled glutathione or placebo for eight weeks; the final sample included sixteen. Peak flow and self-rated improvement favored treatment. The report also summarized the direction of thirteen outcomes; favorable direction did not mean that each outcome individually reached significance. Primary report
Our appraisal: direction counts are not thirteen successful endpoints
When several related outcomes move in the same direction, that can motivate further investigation. It does not create thirteen independent confirmations, especially when measures reflect overlapping aspects of lung function or symptoms. A full review should identify the primary analysis and the method used to handle multiple comparisons.
Peak flow, FEV1 and patient-reported improvement answer different questions. A positive result on one should not be rewritten as a uniform improvement in pulmonary function. The clinical importance and precision of each estimate also matter, particularly with a small analyzed sample.
Losses between randomization and analysis need explanation. Reasons for withdrawal and the distribution between groups can affect interpretation even when only a few participants are missing. Masking deserves attention as well because an inhaled preparation may have sensory characteristics that differ from its comparator.
This historical pilot belongs in the evidence timeline alongside later, larger trials, not above them. It also concerns a specific buffered inhaled formulation, not oral or intravenous glutathione. The absence of noted treatment adverse events in a small short study cannot establish broad safety or justify home preparation of an inhaled product.
Frequently asked questions
How many participants were randomized?
Nineteen.
Was the final analyzed sample the same size?
No; sixteen were described.
Did selected outcomes favor treatment?
Yes.
Were all thirteen outcomes individually positive tests?
That is not what the directional summary establishes.
Is peak flow interchangeable with FEV1?
No.
Does the finding transfer to every glutathione route?
No.
Does this establish comprehensive safety?
No.